Poolbeg Pharma PLC POLBF
0.10 USD 0.00 (+0.00%)
At closeNov 4, 2026, 4:00 PM EST
0.095 Day range 0.095
0.0425 52-week range 0.1154
- YTD
- +125.41%
- 1 year
- +125.41%
News
proactiveinvestors.com Poolbeg Pharma's Korean patent grant bolsters Cavendish's ‘buy' case Poolbeg Pharma PLC (AIM:POLB) secured a South Korean patent for POLB 001, with Cavendish retaining its ‘buy' rating and unchanged 19.0 pence target, citing potential partnering benefits. The patent…
proactiveinvestors.com Poolbeg secures South Korean cancer immunotherapy-induced CRS patent Poolbeg Pharma PLC (AIM:POLB), the clinical-stage biopharmaceutical company, has secured a South Korean patent for POLB 001 to prevent cytokine release syndrome (CRS) induced by cancer immunotherapy.…
proactiveinvestors.com Poolbeg Pharma retains ‘buy' rating at Cavendish after safety review allows trial to continue Cavendish, the City broker, has kept its ‘buy' rating on biopharmaceutical company Poolbeg Pharma PLC (AIM:POLB) after a positive safety review allowed its lead drug, POLB 001, to continue without…
proactiveinvestors.com Poolbeg Pharma funded to finish both trials as it courts partners for cancer drug Poolbeg Pharma PLC (AIM:POLB) says both of its clinical programmes are now funded through to completion, with cash expected to last into the second quarter of 2028. The focus for the rest of the year…
proactiveinvestors.com Poolbeg Pharma doses eight patients in cancer side-effect trial Poolbeg Pharma PLC (AIM:POLB) has dosed eight patients in its TOPICAL trial, which is testing whether its drug POLB 001 can prevent a dangerous side effect of cancer immunotherapy. The trial aims to…
seekingalpha.com Poolbeg Pharma PLC (POLBF) Shareholder/Analyst Call Transcript Poolbeg Pharma PLC (POLBF) Shareholder/Analyst Call Transcript
proactiveinvestors.com Poolbeg Pharma trial progress strengthens Cavendish case for 19p target Poolbeg Pharma PLC's (AIM:POLB) lead clinical programme has reached another milestone after an interim safety review cleared its TOPICAL trial to continue without changes, prompting Cavendish to…
proactiveinvestors.com Poolbeg Pharma gets green light to continue clinical trial Poolbeg Pharma PLC (AIM:POLB) told investors that its POLB 001 TOPICAL clinical trial will continue as planned after an interim safety review recommended no changes to the study protocol. Patient…
proactiveinvestors.co.uk Poolbeg wins Israeli patent nod for lead cancer immunotherapy drug Poolbeg Pharma PLC (AIM:POLB) has secured a Notice of Allowance from the Israeli Patent Office for its POLB 001 cancer immunotherapy-induced cytokine release syndrome patent application. The…
proactiveinvestors.co.uk Poolbeg Pharma raises £3.5m to support key trial and GLP-1 progress Poolbeg Pharma PLC (AIM:POLB), the clinical-stage biopharmaceutical, has raised £3.5 million before expenses through a share placing. Cathal Friel, executive chair, subscribed for £250,000 of the…
proactiveinvestors.co.uk Cavendish sees multi-billion-dollar prize as Poolbeg begins pivotal trial Cavendish has reiterated its 'buy' rating on Poolbeg Pharma PLC (AIM:POLB), arguing that the drug developer's first patient dosing marks the start of a value-creating period for the shares. The…
proactiveinvestors.co.uk Poolbeg doses first patient in cancer immunotherapy safety trial Poolbeg Pharma PLC (AIM:POLB), a clinical-stage biopharmaceutical company focused on cancer immunotherapy, has dosed the first patient in its POLB 001 TOPICAL clinical trial. The AIM-listed company…
proactiveinvestors.co.uk Poolbeg Pharma secures South African patent for lead drug candidate Poolbeg Pharma PLC (AIM:POLB), the biopharmaceutical company focused on cancer immunotherapy, said it had been granted a patent in South Africa for its lead drug candidate, POLB 001. The patent…
proactiveinvestors.co.uk Poolbeg's European patent win bolsters partnering case before summer trial data, says Cavendish Shares in PPoolbeg Pharma PLC (AIM:POLB) rose 3% to 7.8p on Tuesday, taking their gain for the year to date to around 100%, after the drug developer secured a key European patent. The European Patent…
proactiveinvestors.co.uk European patent boosts Poolbeg Pharma's POLB 001 IP portfolio Poolbeg Pharma PLC (AIM:POLB), the clinical-stage biopharmaceutical company, has been granted a European patent for its POLB 001 treatment in cancer immunotherapy-induced cytokine release syndrome…
proactiveinvestors.co.uk Poolbeg Pharma has begun an exciting new clinical trial - ICYMI Poolbeg Pharma PLC (AIM:POLB) this week announced the activation of clinical trial sites for its POLB 001 programme, marking the start of patient enrolment in a study designed to prevent cytokine…
proactiveinvestors.co.uk Poolbeg Pharma shows clinical progress with latest updates Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) said it has activated the first clinical site for its first-in-patient POLB 001 TOPICAL trial, moving its lead cancer immunotherapy programme into…
proactiveinvestors.com Cavendish says FDA alignment de-risks Poolbeg Pharma's lead cancer therapy programme for partners Shares Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, were up 9% following the positive outcome of a...
proactiveinvestors.co.uk Cavendish says FDA alignment de-risks Poolbeg Pharma's lead cancer therapy programme for partners Shares Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, were up 9% following the positive outcome of a pre-investigational new drug meeting with the…
proactiveinvestors.co.uk Poolbeg Pharma gets positive FDA feedback for development pathway of lead cancer therapy asset Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, has received positive feedback from the US Food and Drug Administration (FDA) in a…